Cargando…

Su1485: COVID-19 VACCINE-INDUCED ANTIBODY RESPONSES ARE IMPAIRED IN IBD PATIENTS TREATED WITH INFLIXIMAB, USTEKINUMAB OR TOFACITINIB, BUT NOT THIOPURINES OR VEDOLIZUMAB

Detalles Bibliográficos
Autores principales:	Alexander, James L., Kennedy, Nick, Ibraheim, Hajir, Anandabaskaran, Sulak, Saifuddin, Aamir, Seoane, Rocio Castro, Liu, Zhigang, Nice, Rachel, Bewshea, Claire M., D'Mello, Andrea, Constable, Laura E., Jones, Gareth-Rhys, Balarajah, Sharmili, Fiorentino, Francesca, Sebastian, Shaji, Irving, Peter M., Hicks, Lucy C., Williams, Horace R., Kent, Alexandra J., Parkes, Miles, Kok, Klaartje, Patel, Kamal V, Altmann, Daniel, Boyton, Rosemary, Goodhand, James, Hart, Ailsa, Lees, Charlie W., Ahmad, Tariq, Powell, Nick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AGA Institute. Published by Elsevier Inc. 2022
Materias:	AGA Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212464/ http://dx.doi.org/10.1016/S0016-5085(22)61407-0

Ejemplares similares

Su1611: POOR RESPONSE TO ANTI-SARS-COV-2 VACCINATION IN IMMUNOSUPPRESSED INFLAMMATORY BOWEL DISEASE PATIENTS IS ASSOCIATED WITH ALTERED GUT MICROBIOTA FUNCTION
por: Alexander, James L., et al.
Publicado: (2022)

COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study
por: Alexander, James L, et al.
Publicado: (2022)

COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study
por: Alexander, James L, et al.
Publicado: (2022)

Neutralising antibody responses against SARS-CoV-2 Omicron BA.4/5 and wild-type virus in patients with inflammatory bowel disease following three doses of COVID-19 vaccine (VIP): a prospective, multicentre, cohort study
por: Liu, Zhigang, et al.
Publicado: (2023)

855 PATIENT-LED REMOTE INTRACAPILLARY PHARMACOKINETIC SAMPLING (FINGERPRICKS): VALIDATION AND ACCEPTABILITY FOR HOME THERAPEUTIC DRUG MONITORING IN PATIENTS WITH IBD IN THE COVID-19 PANDEMIC
por: Chee, Desmond, et al.
Publicado: (2021)

Su1500: COMPARATIVE EFFICACY AND SAFETY OF OZANIMOD AND USTEKINUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
por: Dubinsky, Marla C., et al.
Publicado: (2022)

Fr494 THE IMPACT OF VEDOLIZUMAB THERAPY ON COVID-19 OUTCOMES IN ADULT IBD PATIENTS IN THE SECURE-IBD REGISTRY
por: Agrawal, Manasi, et al.
Publicado: (2021)

EP1276: USTEKINUMAB HAS COMPARABLE LONG-TERM EFFECTIVENESS AS ANTI-TNF AGENTS IN BIOLOGIC-NAÏVE PATIENTS WITH CROHN'S DISEASE
por: Shiga, Hisashi, et al.
Publicado: (2022)

1163: BOTH VEDOLIZUMAB AND ANTI-TNF THERAPY ARE ASSOCIATED WITH ATTENUATION OF SEROLOGICAL AND NEUTRALIZING RESPONSES TO SARS-COV-2 INFECTION IN INFLAMMATORY BOWEL DISEASE
por: Wellens, Judith, et al.
Publicado: (2022)

Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab
por: Lin, Simeng, et al.
Publicado: (2022)

Neutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study
por: Liu, Zhigang, et al.
Publicado: (2023)

Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience
por: Ibraheim, Hajir, et al.
Publicado: (2020)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Adalimumab/ustekinumab/vedolizumab: COVID-19 infection: 7 case reports
Publicado: (2022)

Ustekinumab and Vedolizumab Are Equally Safe and Effective in Elderly Crohn’s Disease Patients
por: Gebeyehu, Gerum Gashaw, et al.
Publicado: (2022)

The Risk of Tuberculosis in Patients With Inflammatory Bowel Disease Treated With Vedolizumab or Ustekinumab in Korea
por: Choi, Myeong Geun, et al.
Publicado: (2022)

Prevalence of Immunomodulator Use as Combination Therapy With Vedolizumab or Ustekinumab in Inflammatory Bowel Disease
por: Lutz, Megan, et al.
Publicado: (2023)

Fr493 DISEASE ACTIVITY IS ASSOCIATED WITH COVID-19 OUTCOMES IN IBD PATIENTS WITH EFFECT MODIFICATION BY AGE
por: Ricciuto, Amanda, et al.
Publicado: (2021)

Pathology of immune-mediated tissue lesions following treatment with immune checkpoint inhibitors
por: Ibraheim, Hajir, et al.
Publicado: (2019)

Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease
por: Restellini, Sophie, et al.
Publicado: (2021)

Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients
por: Chanchlani, Neil, et al.
Publicado: (2021)

The gut microbiota and metabolome are associated with diminished COVID-19 vaccine-induced antibody responses in immunosuppressed inflammatory bowel disease patients
por: Alexander, James L., et al.
Publicado: (2023)

Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn’s disease
por: Newman, Kira L., et al.
Publicado: (2023)

Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study
por: Burgevin, Alice, et al.
Publicado: (2022)

The Pathophysiology of Impulse control Disorders in Parkinson Disease
por: Balarajah, Sharmili, et al.
Publicado: (2013)

Patient-Preferences Favoring Treatment Discontinuation Are Reduced With Vedolizumab and Ustekinumab Compared With TNF Antagonists in Inflammatory Bowel Disease
por: Kumar, Anand, et al.
Publicado: (2020)

Comparison of surgery rates in biologic-naïve patients with Crohn’s disease treated with vedolizumab or ustekinumab: findings from SOJOURN
por: Vu, Michelle, et al.
Publicado: (2023)

Where Are We and Where to Next?—The Future of Perianal Crohn’s Disease Management
por: Anandabaskaran, Sulak, et al.
Publicado: (2023)

Padua and the Tudors: English students in Italy, 1485–1603
por: Nutton, Vivian
Publicado: (2000)

1485 Measles among immigrant children in Kirikkale, Turkey
por: Bulbul, Selda Fatma, et al.
Publicado: (2014)

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
por: Holko, Przemysław, et al.
Publicado: (2018)

Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment
por: Biemans, Vince B. C., et al.
Publicado: (2020)

Differences in the placental pharmacokinetics of vedolizumab and ustekinumab during pregnancy in women with inflammatory bowel disease: a prospective multicentre study
por: Mitrova, Katarina, et al.
Publicado: (2021)

AGA Institute Rapid Review and Recommendations on the Role of Pre-Procedure SARS-CoV-2 Testing and Endoscopy
por: Sultan, Shahnaz, et al.
Publicado: (2020)

AGA Institute Rapid Review of the Gastrointestinal and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19
por: Sultan, Shahnaz, et al.
Publicado: (2020)

AGA-Mitteilungen
Publicado: (2020)

AGA-Mitteilungen
Publicado: (2020)

Su1189 SAFETY OF IMMUNE CHECKPOINT INHIBITORS IN PATIENTS WITH PREEXISTING INFLAMMATORY BOWEL DISEASE AND MICROSCOPIC COLITIS
por: Grover, Shilpa, et al.
Publicado: (2020)

Su1187 ALMOST EVERYTHING CAUSES DIARRHEA: GASTROINTESTINAL MANIFESTATIONS OF ACUTE RESPIRATORY INFECTIONS AMONG 3,510 INDIVIDUALS IN A COMMUNITY-BASED STUDY
por: Newman, Kira L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_b5ae4shtuhb4t1462djmk3kivq